Intuitive Surgical, Inc. (NASDAQ:ISRG) Stock Position Decreased by Patron Partners LLC

Patron Partners LLC lowered its holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 1.2% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,823 shares of the medical equipment provider’s stock after selling 22 shares during the period. Patron Partners LLC’s holdings in Intuitive Surgical were worth $896,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Ridgewood Investments LLC bought a new stake in shares of Intuitive Surgical during the second quarter valued at approximately $26,000. Godsey & Gibb Inc. increased its holdings in shares of Intuitive Surgical by 140.0% during the third quarter. Godsey & Gibb Inc. now owns 60 shares of the medical equipment provider’s stock valued at $29,000 after purchasing an additional 35 shares during the period. Creekmur Asset Management LLC raised its stake in shares of Intuitive Surgical by 200.0% during the first quarter. Creekmur Asset Management LLC now owns 63 shares of the medical equipment provider’s stock valued at $25,000 after purchasing an additional 42 shares in the last quarter. LGT Financial Advisors LLC lifted its holdings in Intuitive Surgical by 415.4% in the second quarter. LGT Financial Advisors LLC now owns 67 shares of the medical equipment provider’s stock worth $30,000 after purchasing an additional 54 shares during the period. Finally, Delos Wealth Advisors LLC grew its position in Intuitive Surgical by 380.0% in the 1st quarter. Delos Wealth Advisors LLC now owns 72 shares of the medical equipment provider’s stock valued at $29,000 after buying an additional 57 shares in the last quarter. 83.64% of the stock is currently owned by institutional investors and hedge funds.

Intuitive Surgical Price Performance

Shares of Intuitive Surgical stock opened at $535.75 on Tuesday. The firm has a fifty day moving average price of $494.78 and a two-hundred day moving average price of $453.94. Intuitive Surgical, Inc. has a fifty-two week low of $281.12 and a fifty-two week high of $542.59. The company has a market cap of $190.82 billion, a PE ratio of 86.13, a price-to-earnings-growth ratio of 5.27 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last announced its quarterly earnings data on Thursday, October 17th. The medical equipment provider reported $1.56 EPS for the quarter, topping analysts’ consensus estimates of $1.24 by $0.32. The company had revenue of $2.04 billion during the quarter, compared to the consensus estimate of $2.01 billion. Intuitive Surgical had a return on equity of 13.41% and a net margin of 28.51%. Analysts expect that Intuitive Surgical, Inc. will post 5.45 earnings per share for the current fiscal year.

Insider Activity at Intuitive Surgical

In other Intuitive Surgical news, Director Amy L. Ladd sold 450 shares of Intuitive Surgical stock in a transaction on Friday, September 13th. The stock was sold at an average price of $490.28, for a total transaction of $220,626.00. Following the completion of the transaction, the director now directly owns 821 shares of the company’s stock, valued at approximately $402,519.88. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, General Counsel Gary Loeb sold 300 shares of the stock in a transaction on Monday, September 9th. The stock was sold at an average price of $475.00, for a total transaction of $142,500.00. Following the sale, the general counsel now owns 1,595 shares in the company, valued at approximately $757,625. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Amy L. Ladd sold 450 shares of the firm’s stock in a transaction dated Friday, September 13th. The shares were sold at an average price of $490.28, for a total transaction of $220,626.00. Following the completion of the sale, the director now owns 821 shares of the company’s stock, valued at $402,519.88. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 68,006 shares of company stock valued at $33,727,766 in the last 90 days. 0.90% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of research analysts recently commented on ISRG shares. Citigroup raised their price objective on shares of Intuitive Surgical from $512.00 to $560.00 and gave the company a “buy” rating in a research note on Thursday, August 22nd. Royal Bank of Canada boosted their price objective on Intuitive Surgical from $525.00 to $555.00 and gave the stock an “outperform” rating in a research note on Friday, October 18th. Barclays raised their target price on Intuitive Surgical from $430.00 to $490.00 and gave the company an “overweight” rating in a research note on Thursday, July 18th. Redburn Atlantic raised shares of Intuitive Surgical from a “neutral” rating to a “buy” rating and upped their price target for the company from $380.00 to $510.00 in a report on Friday, August 2nd. Finally, Mizuho lifted their price objective on shares of Intuitive Surgical from $440.00 to $500.00 in a research note on Thursday, October 17th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and fourteen have given a buy rating to the company. Based on data from MarketBeat, Intuitive Surgical presently has an average rating of “Moderate Buy” and a consensus target price of $513.74.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.